Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 13, 2024
SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September
VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations between the Parties, at close
Read more at globenewswire.com0.37
-0.03 (-7.48%)
Find more stocks in the Stock Screener
MCRB Latest News and Analysis
5 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
6 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
